Bexarotene salvage therapy in a patient with refractory erythrodermic mycosis fungoides after failure on interferon/PUVA and methotrexate.
Dalle
Stéphane
S
Department of Dermatology, Hospices Civils de Lyon, Hôpital de L'Hôtel-Dieu, Lyon, France. stephane.dalle@chu-lyon.fr
Thomas
Luc
L
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077610:Bexarotene; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D009182:Mycosis Fungoides / Q000188:drug therapy* / Q000473:pathology; D011701:PUVA Therapy; D016879:Salvage Therapy; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D013764:Tetrahydronaphthalenes; D007372:Interferons; D000077610:Bexarotene; D008727:Methotrexate